CL2020000124A1 - Composiciones sólidas orales de betahistina de liberación prolongada no pulsátil. - Google Patents
Composiciones sólidas orales de betahistina de liberación prolongada no pulsátil.Info
- Publication number
- CL2020000124A1 CL2020000124A1 CL2020000124A CL2020000124A CL2020000124A1 CL 2020000124 A1 CL2020000124 A1 CL 2020000124A1 CL 2020000124 A CL2020000124 A CL 2020000124A CL 2020000124 A CL2020000124 A CL 2020000124A CL 2020000124 A1 CL2020000124 A1 CL 2020000124A1
- Authority
- CL
- Chile
- Prior art keywords
- betahistine
- dissolves
- weight
- hours
- pulsatile
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Inorganic Chemistry (AREA)
- Molecular Biology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Cosmetics (AREA)
Abstract
La presente invención se refiere a una composición sólida oral de liberación prolongada de 24 horas no pulsátil que comprende una cantidad de betahistina, o de una sal farmacéuticamente aceptable de esta, equivalente a 48 mg de diclorhidrato de betahistina, junto con uno o más excipientes o portadores farmacéuticamente aceptables, donde la composición presenta un perfil de disolución de acuerdo con el cual: se disuelve hasta un 30% en peso de betahistina en 1 hora; se disuelve de un 35% a un 45% en peso de betahistina en 2 horas; se disuelve de un 46% a un 60% en peso de betahistina en 4 horas; se disuelve de un 61% a un 80% en peso de betahistina en 8 horas; se disuelve de un 81% a un 97% en peso de betahistina en 16 horas; y se disuelve de un 98% a un 100% en peso de betahistina en 24 horas. También se refiere a su uso en terapia, particularmente en el tratamiento de una enfermedad o afección vestibular, más particularmente en el tratamiento de la enfermedad de Ménière.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN201721025857 | 2017-07-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2020000124A1 true CL2020000124A1 (es) | 2020-09-21 |
Family
ID=59829185
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2020000124A CL2020000124A1 (es) | 2017-07-20 | 2020-01-16 | Composiciones sólidas orales de betahistina de liberación prolongada no pulsátil. |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US11433058B2 (es) |
| EP (2) | EP3431078B1 (es) |
| JP (1) | JP7084950B2 (es) |
| CN (1) | CN110891551A (es) |
| AR (1) | AR112281A1 (es) |
| AU (1) | AU2018302771B2 (es) |
| BR (1) | BR112020000977A2 (es) |
| CA (1) | CA3069282A1 (es) |
| CL (1) | CL2020000124A1 (es) |
| CO (1) | CO2020001742A2 (es) |
| DK (1) | DK3431078T3 (es) |
| ES (1) | ES2862209T3 (es) |
| HR (1) | HRP20210570T1 (es) |
| LT (1) | LT3431078T (es) |
| MX (1) | MX2020000702A (es) |
| PH (1) | PH12020500001A1 (es) |
| PL (1) | PL3431078T3 (es) |
| PT (1) | PT3431078T (es) |
| SA (1) | SA520411067B1 (es) |
| UY (1) | UY37798A (es) |
| WO (1) | WO2019016668A1 (es) |
| ZA (1) | ZA202000030B (es) |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1309591B1 (it) * | 1999-03-05 | 2002-01-24 | Formenti Farmaceutici Spa | Composizioni a rilascio controllato di betaistina. |
| CA2452872A1 (en) * | 2001-07-06 | 2003-01-16 | Endo Pharmaceuticals, Inc. | Parenteral administration of 6-hydroxy-oxymorphone for use as an analgesic |
| TWI319713B (en) * | 2002-10-25 | 2010-01-21 | Sustained-release tramadol formulations with 24-hour efficacy | |
| EP1493435B1 (en) * | 2003-07-04 | 2008-05-14 | FARMACEUTICI FORMENTI S.p.A. | Controlled Release Compositions of Betahistine |
| WO2012131722A1 (en) * | 2011-03-30 | 2012-10-04 | Sun Pharma Advanced Research Company Ltd. | Controlled release composition of betahistine |
| DE102012105528A1 (de) | 2012-06-25 | 2014-01-02 | Hennig Arzneimittel Gmbh & Co. Kg | Arzneiform zur Freisetzung von Wirkstoffen |
| WO2014174073A1 (en) * | 2013-04-26 | 2014-10-30 | Sandoz Ag | Sustained release formulations of tofacitinib |
-
2017
- 2017-09-04 ES ES17189264T patent/ES2862209T3/es active Active
- 2017-09-04 EP EP17189264.9A patent/EP3431078B1/en active Active
- 2017-09-04 PL PL17189264T patent/PL3431078T3/pl unknown
- 2017-09-04 DK DK17189264.9T patent/DK3431078T3/da active
- 2017-09-04 LT LTEP17189264.9T patent/LT3431078T/lt unknown
- 2017-09-04 PT PT171892649T patent/PT3431078T/pt unknown
-
2018
- 2018-07-05 UY UY0001037798A patent/UY37798A/es unknown
- 2018-07-16 EP EP18835809.7A patent/EP3654954A4/en not_active Withdrawn
- 2018-07-16 JP JP2019570397A patent/JP7084950B2/ja active Active
- 2018-07-16 BR BR112020000977-6A patent/BR112020000977A2/pt unknown
- 2018-07-16 CA CA3069282A patent/CA3069282A1/en active Pending
- 2018-07-16 CN CN201880047204.7A patent/CN110891551A/zh active Pending
- 2018-07-16 MX MX2020000702A patent/MX2020000702A/es unknown
- 2018-07-16 WO PCT/IB2018/055233 patent/WO2019016668A1/en unknown
- 2018-07-16 US US16/632,500 patent/US11433058B2/en active Active
- 2018-07-16 AU AU2018302771A patent/AU2018302771B2/en active Active
- 2018-07-19 AR ARP180102029 patent/AR112281A1/es unknown
-
2020
- 2020-01-02 ZA ZA2020/00030A patent/ZA202000030B/en unknown
- 2020-01-02 PH PH12020500001A patent/PH12020500001A1/en unknown
- 2020-01-16 SA SA520411067A patent/SA520411067B1/ar unknown
- 2020-01-16 CL CL2020000124A patent/CL2020000124A1/es unknown
- 2020-02-14 CO CONC2020/0001742A patent/CO2020001742A2/es unknown
-
2021
- 2021-04-09 HR HRP20210570TT patent/HRP20210570T1/hr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20210161871A1 (en) | 2021-06-03 |
| EP3654954A4 (en) | 2021-06-16 |
| LT3431078T (lt) | 2021-05-10 |
| AU2018302771A1 (en) | 2020-01-16 |
| WO2019016668A1 (en) | 2019-01-24 |
| UY37798A (es) | 2019-01-02 |
| PH12020500001A1 (en) | 2020-09-14 |
| MX2020000702A (es) | 2020-10-14 |
| EP3654954A1 (en) | 2020-05-27 |
| JP2020528045A (ja) | 2020-09-17 |
| CA3069282A1 (en) | 2019-01-24 |
| RU2020101925A (ru) | 2021-08-20 |
| AR112281A1 (es) | 2019-10-09 |
| US11433058B2 (en) | 2022-09-06 |
| JP7084950B2 (ja) | 2022-06-15 |
| CO2020001742A2 (es) | 2020-02-28 |
| PL3431078T3 (pl) | 2021-07-12 |
| RU2020101925A3 (es) | 2021-08-27 |
| BR112020000977A2 (pt) | 2020-07-14 |
| DK3431078T3 (da) | 2021-04-19 |
| PT3431078T (pt) | 2021-04-21 |
| SA520411067B1 (ar) | 2022-09-28 |
| AU2018302771B2 (en) | 2022-05-12 |
| EP3431078A1 (en) | 2019-01-23 |
| ES2862209T3 (es) | 2021-10-07 |
| EP3431078B1 (en) | 2021-01-20 |
| HRP20210570T1 (hr) | 2021-09-03 |
| CN110891551A (zh) | 2020-03-17 |
| ZA202000030B (en) | 2021-08-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UY37998A (es) | Agentes antivirales contra la hepatitis b | |
| NZ742220A (en) | Pharmaceutical compositions comprising meloxicam | |
| EA201691454A1 (ru) | Композиции придопидина модифицированного высвобождения | |
| NI201000193A (es) | Formulaciones orales de análogos de citidina y métodos de uso de las mismas. | |
| CO6650415A2 (es) | Nuevas formas de dosificacion de liberación modificada de un inhibidor de la xantina oxidorreductasa o de inhibidoes de xantina oxidasa | |
| JP2010222367A5 (es) | ||
| UA113165C2 (xx) | Застосування комбінації баклофену і акампросату для лікування неврологічних захворювань та композиція, яка містить баклофен і акампросат | |
| CL2009000349A1 (es) | Compuestos derivados de 4,5-dihidro-oxazol-2-ilamina; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento de la enfermedad de alzheimer. | |
| BRPI0509863A (pt) | liberação de fármaco para fundo de olho | |
| AR057946A1 (es) | Formulacion de zonisamida de liberacion sostenidda | |
| EA201490254A1 (ru) | Комбинированное лечение гепатита с | |
| AR070025A1 (es) | Uso de derivados de 1-amino-alquilciclohexano para el tratamiento del tinnitus coclear y composicion farmaceutica | |
| CY1118057T1 (el) | Φαρμακευτικη συνθεση για στοματικη χορηγηση | |
| ATE536172T1 (de) | Ezetimibzusammensetzungen | |
| AR063538A1 (es) | Tratamiento de la enfermedad de parkinson | |
| CY1108196T1 (el) | Αντιμικροβιακες φαρμακευτικες συνθεσεις χορηγουμενες απο το στομα | |
| CY1113726T1 (el) | Χρηση της πασιρεοτιδης για την αντιμετωπιση της ενδογενους υπερινσουλιναιμικης υπογλυκαιμιας | |
| MA32841B1 (fr) | Composés de cycloundeca depsipeptides et leur utilisation comme médicament | |
| EA201791138A1 (ru) | Фармацевтическая композиция, ее приготовление и применения | |
| PH12019500618A1 (en) | Pharmaceutical composition and method for treatment of non-alcoholic fatty liver disease | |
| AR099299A1 (es) | Inhibidor de la proteína de transferencia de éster de colesterilo (cetp) y composiciones farmacéuticas que comprenden dicho inhibidor para uso en el tratamiento o prevención de enfermedades cardiovasculares | |
| BR112012020377A8 (pt) | utilização de um ou mais selecionado do grupo constituído por um composto da fórmula (i), uma mistura racêmica-diastereomérica e um isômero óptico do referido composto, e um sal farmaceuticamente aceitável e uma pródroga do mesmo, método, composição farmacêutica e kit para tratamento de caquexia e embalagem comercial | |
| WO2014119985A3 (es) | Composición farmacéutica con un inhibidor selectivo de la enzima fosfodiesterasa en forma de gel oral | |
| CO2023009085A2 (es) | Pauta posológica de levodopa | |
| ECSP088285A (es) | 3-(2-dimetilaminometil ciclohexil) fenol formulación retardada. |